SHINPOONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SHINPOONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩4622B. At end of 2025 it was ₩7827B. Ranked #461 of 2,405 in KR market (top 19%), #294 of 778 on KOSPI (top 38%), #51 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 462.15B KRW | KR#461/2,405 Sec#51/231 |
| Revenue | 239.07B KRW | KR#940/2,405 Sec#53/231 |
| Net Income | -746.5M KRW | KR—/2,405 Sec—/231 |
| Total Assets | 366.50B KRW | KR#922/2,405 Sec#58/231 |
| Net Assets | 278.04B KRW | KR#753/2,405 Sec#49/231 |
| Employees | 832 | KR#298/2,405 Sec#24/231 |
| Value | ||
| P/B | 1.66x | KR#1,873/2,405 Sec#139/231 |
| P/S | 1.94x | KR#1,837/2,405 Sec#106/231 |
| EV/EBITDA | 173.30x | KR#1,520/2,405 Sec#104/231 |
| FCF Yield | 2.98% | KR#1,005/2,405 Sec#63/231 |
| Profitability | ||
| ROE | -0.27% | KR#1,561/2,405 Sec#108/231 |
| ROA | -0.20% | KR#1,571/2,405 Sec#108/231 |
| Op. Margin | 1.13% | KR#1,489/2,405 Sec#104/231 |
| Revenue Growth | 6.21% | KR#1,116/2,405 Sec#109/231 |
| Financial Health | ||
| Debt Ratio | 31.82% | KR#620/2,405 Sec#73/231 |
| Total Debt | 52.40B KRW | KR#986/2,405 Sec#67/231 |
| FCF | 13.78B KRW | KR#622/2,405 Sec#34/231 |
| Cash | 48.09B KRW | KR#754/2,405 Sec#45/231 |
| Current Ratio | 2.86x | KR#588/2,405 Sec#78/231 |
| Net Debt/EBITDA | 1.60x | KR#798/2,405 Sec#55/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -38.52% | KR#1,661/2,405 Sec#134/231 |
| 1M Return | -9.95% | KR#1,157/2,405 Sec#111/231 |
| From 52W High | -47.61% | KR#1,062/2,405 Sec#76/231 |
| 1Y MDD | -54.05% | KR#1,134/2,405 Sec#94/231 |
| Trading | ||
| Volume | 104,877 shares | KR#612/2,405 Sec#62/231 |
| Trading Value | 868.8M KRW | KR#630/2,405 Sec#64/231 |
| Foreign Own. | 4.35% | KR#973/2,405 Sec#87/231 |
| Per Share | ||
| EPS | -13 KRW | KR—/2,405 Sec—/231 |
| BPS | 5,006 KRW | KR#1,502/2,405 Sec#108/231 |
Company Info
Established in 1962 and listed on the Korea Exchange in 1990, the company is a mid-sized pharmaceutical enterprise primarily focusing on the manufacturing and sale of finished pharmaceutical products and active pharmaceutical ingredients. It operates six subsidiaries for overseas market entry in countries like Vietnam, Philippines, Myanmar, and the United States. The company concentrates its mid-to-long-term capabilities on global new drug development and secures domestic market competitiveness by launching improved new drugs and first generics, and fostering highly profitable items into mega-products.